EMD-40261

Single-particle
3.7 Å
EMD-40261
3D View Gallery
Deposition: 31/03/2023
Map released: 29/05/2024
Last modified: 20/08/2025
Overview 3D View Sample Experiment Validation Additional data Links
Overview 3D View Sample Experiment Validation Additional data Links

EMD-40261
Download
3D volume (map.gz) Experimental metadata (xml) Experimental Metadata (cif.gz)
Map-only Validation report (pdf.gz) Map-only Validation report (cif.gz) Map-only Validation report (xml.gz)
EMICSS annotations (xml)

DDB1/CRBN in complex with ARV-471 and the ER ligand-binding domain

EMD-40261

Single-particle
3.7 Å
EMD-40261
3D View Gallery
Deposition: 31/03/2023
Map released: 29/05/2024
Last modified: 20/08/2025
Overview 3D View Sample Experiment Validation Additional data Links
Sample Organism: Homo sapiens
Sample: Ternary complex of DDB1/CRBN, ARV-471, and the ER ligand-binding domain

Deposition Authors: Digianantonio K , Drulyte I , Gough S, Bekes M , Taylor I
Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models.
Gough SM , Flanagan JJ , Teh J , Andreoli M , Rousseau E , Pannone M , Bookbinder M , Willard R , Davenport K , Bortolon E , Cadelina G , Gordon D , Pizzano J , Macaluso J , Soto L , Corradi J , Digianantonio K , Drulyte I , Morgan A , Quinn C , Bekes M , Ferraro C , Chen X , Wang G , Dong H , Wang J , Langley DR , Houston J , Gedrich R , Taylor IC
(2024) Clin.Cancer Res. , 30 , 3549 - 3563
PUBMED: 38819400
DOI: doi:10.1158/1078-0432.CCR-23-3465
ISSN: 1078-0432
Grant Support: